| 9.1782 -0.022 (-0.24%) | 05-01 09:31 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 12.19 | 1-year : | 14.23 |
| Resists | First : | 10.43 | Second : | 12.19 |
| Pivot price | 9.19  |
|||
| Supports | First : | 7.88 | Second : | 6.3 |
| MAs | MA(5) : | 9.12  |
MA(20) : | 8.95 |
| MA(100) : | 6.1 |
MA(250) : | 7.76 |
|
| MACD | MACD : | 0.6 |
Signal : | 0.7 |
| %K %D | K(14,3) : | 45.4 |
D(3) : | 48.6 |
| RSI | RSI(14): 59.5 |
|||
| 52-week | High : | 24.38 | Low : | 2.96 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ ELTX ] has closed below upper band by 49.6%. Bollinger Bands are 26.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 9.21 - 9.24 | 9.24 - 9.28 |
| Low: | 8.76 - 8.8 | 8.8 - 8.84 |
| Close: | 9.13 - 9.19 | 9.19 - 9.26 |
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases. The company's lead product candidate is ELI-002, an AMP therapeutic vaccine for the treatment of KRAS-driven cancers. It is also developing ELI-004, an AMP-modified CpG adjuvant, a component of ELI-002; ELI-007, a lymph node targeted AMP-peptide vaccine for mutant BRAF-driven cancers; ELI-008, a multivalent lymph node targeted AMP-peptide vaccine for mutant TP53-expressing cancers; ELI-005, a vaccine candidate for the prevention of COVID-19; ELI-011 for the treatment of hematological cancers; and ELI-012, a mKRAS TCR T cell AMP-lifier designs to use in combination with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers. The company is headquartered in Boston, Massachusetts.
Thu, 25 Apr 2024
Elicio Therapeutics to Present New Preliminary Data from the Ongoing AMPLIFY-7P Phase 1/2 Study of ELI-002 7P in ... - GlobeNewswire
Mon, 15 Apr 2024
Retail investors who hold 45% of Elicio Therapeutics, Inc. (NASDAQ:ELTX) gained 14%, insiders profited as well - Simply Wall St
Thu, 04 Apr 2024
Unlocking The Power Of Immunotherapy: Elicio Therapeutics' (NASDAQ: ELTX) Novel AMP Platform - Elicio The - Benzinga
Fri, 29 Mar 2024
Elicio Therapeutics Reports 2023 Financial Results and Provides Corporate Updates - GlobeNewswire
Mon, 18 Mar 2024
Healthcare Stocks Moving Monday: CDXC, AHG, IMRX, ELTX, CMAX, ABEO, ZJYL, WGS - InvestorsObserver
Mon, 18 Mar 2024
Elicio Therapeutics Announces $6.0 Million Private Placement Financing - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 10 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 45 (%) |
| Held by Institutions | 5.3 (%) |
| Shares Short | 40 (K) |
| Shares Short P.Month | 24 (K) |
| EPS | -6.97 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.17 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -89.7 % |
| Return on Equity (ttm) | -347 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -3.46 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -33 (M) |
| Levered Free Cash Flow | -17 (M) |
| PE Ratio | -1.33 |
| PEG Ratio | 0 |
| Price to Book value | 7.79 |
| Price to Sales | 0 |
| Price to Cash Flow | -2.88 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|